A Randomized, Double-blind, Placebo-controlled, Single-dose, 6-Period Crossover Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Single-dose, 6-Period Crossover Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs BPN 14770 (Primary) ; Donepezil; Scopolamine
  • Indications Alzheimer's disease; Cognition disorders
  • Focus Therapeutic Use
  • Sponsors Tetra Discovery Partners
  • Most Recent Events

    • 07 Nov 2017 Status changed from active, no longer recruiting to completed, according to a Tetra Discovery Partners media release.
    • 26 Apr 2017 Planned End Date changed from 1 May 2017 to 1 Jun 2017.
    • 26 Apr 2017 Planned primary completion date changed from 1 Feb 2017 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top